• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Introduction to 5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole (CAS No. 77792-52-0)

5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole, identified by the Chemical Abstracts Service Number (CAS No.) 77792-52-0, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic aromatic molecule has garnered attention due to its structural complexity and potential biological activities. The presence of chlorine substituents at the 5th and 2-chlorophenyl positions enhances its reactivity and interaction with biological targets, making it a valuable scaffold for drug discovery.

The compound belongs to the benzo[c]isoxazole class, a family of molecules known for their diverse pharmacological properties. Benzo[c]isoxazoles have been extensively studied for their roles in modulating various biological pathways, including enzyme inhibition and receptor binding. The structural features of 5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole contribute to its potential as an intermediate in synthesizing novel therapeutic agents.

In recent years, there has been a surge in research focusing on developing small-molecule inhibitors targeting cancer-related pathways. The unique structure of 5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole makes it an attractive candidate for further investigation in this field. Studies have indicated that this compound may exhibit inhibitory effects on kinases and other enzymes involved in tumor progression. Its ability to interact with specific amino acid residues in these enzymes could lead to the development of highly selective inhibitors with minimal side effects.

Moreover, the chlorine atoms in the molecule enhance its lipophilicity, which is a crucial factor in drug bioavailability. This property allows the compound to cross cell membranes more efficiently, potentially improving its therapeutic efficacy. Researchers are exploring its potential as a lead compound for further optimization through structure-activity relationship (SAR) studies.

One of the most promising applications of 5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole is in the treatment of neurological disorders. Preliminary studies suggest that this compound may modulate neurotransmitter systems by interacting with receptors such as serotonin and dopamine. These interactions could have therapeutic implications for conditions like depression, anxiety, and Parkinson's disease. The benzo[c]isoxazole core is known to exhibit neuroprotective properties, making this compound a potential candidate for further development in neuropharmacology.

The synthesis of 5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have been employed to introduce the necessary substituents at specific positions. These methods not only improve efficiency but also minimize unwanted byproducts, ensuring that the final product meets pharmaceutical standards.

Recent advancements in computational chemistry have also played a pivotal role in understanding the molecular interactions of 5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole. Molecular docking studies have been conducted to predict its binding affinity to various biological targets. These simulations provide valuable insights into how the compound interacts with proteins and enzymes at an atomic level, guiding researchers in designing more effective derivatives.

The pharmacokinetic properties of 5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole are another area of interest. Researchers are investigating its absorption, distribution, metabolism, and excretion (ADME) profiles to assess its potential as a drug candidate. Understanding these parameters is essential for predicting how the compound will behave within the human body and for optimizing dosing regimens.

In conclusion, 5-Chloro-3-(2-chlorophenyl)benzo[c]isoxazole (CAS No. 77792-52-0) represents a promising scaffold for developing novel therapeutic agents. Its unique structural features and potential biological activities make it an attractive candidate for further research in oncology, neurology, and other areas of medicine. Continued investigation into this compound will likely yield valuable insights into its mechanisms of action and therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)